Literature DB >> 2946813

Dopamine receptor changes in response to prolonged treatment with L-dopa.

A Groppetti, C Flauto, E Parati, A Vescovi, L Rusconi, M Parenti.   

Abstract

Unilateral lesions of the nigro-striatal dopamine (DA) pathway induced contralateral rotations to apomorphine, increased (3H)-spiroperidol binding and enhanced the sensitivity of striatal adenylate cyclase to DA stimulation. Prolonged L-dopa administration counteracted the increased density of (3H)-spiroperidol binding sites but further enhanced the hypersensitivity of adenylate cyclase to DA and decreased the inhibitory effect of opiates on this enzyme. The apomorphine-induced contralateral rotations were also strongly potentiated. On the contrary the binding of (3H)-SCH-23390 was affected neither by DA nerve degeneration nor by chronic L-dopa treatment. These results suggest that DA-D1 and DA-D2 receptors are differently affected by prolonged L-dopa treatment. The biochemical changes of DA-D1 receptors associated with adenylate cyclase seem to be correlated with the enhanced behavioural responses to apomorphine and could be a consequence of a decreased opiate inhibitory tone on the enzyme. The increased supersensitivity of the DA-D1 receptors may play a role in the clinical changes seen in parkinsonian patients following chronic use of L-dopa.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2946813

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  3 in total

1.  Sustained-release of levodopa: single dose study of a new formulation.

Authors:  M Gerlach; W Kuhn; T Müller; P Klotz; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 2.  Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.

Authors:  A R Braun; M Laruelle; M M Mouradian
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Terguride in the treatment of Parkinson disease: preliminary experience.

Authors:  P Giovannini; I Piccolo; S Genitrini; F Girotti; D Testa; G Scigliano; I Suchy
Journal:  Ital J Neurol Sci       Date:  1990-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.